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SUMMARY Too many patients with photoallergy remain undiagnosed 
due to unsatisfactory knowledge among doctors and limited access to 
photopatch testing. The objectives of this study were to analyze the 
frequency of patients requiring diagnostic work-up for photoallergic 
contact dermatitis among dermatology patients, and to identify the 
causative photosensitizers. This prospective study involved 1000 con-
secutive, first-referred dermatology outpatients. All patients with a 
history of dermatitis induced or aggravated by exposure to light were 
qualified for photopatch testing. In the study group, 36 (3.6%; 95%CI: 
2.4-4.8%) persons required photopatch testing based on their clinical 
symptoms. As the total number of patients requiring patch tests of 
any kind amounted to 205, the percentage of photopatch tested pa-
tients among all patch-tested patients was 17.5% (95%CI: 12.2-22.8%). 
Photoallergic contact dermatitis was ultimately confirmed in 15 (1.5%; 
0.7-2.3%) persons: 7 females and 8 males aged 6-60 (median 33) years. 
Nine patients turned out photoallergic to at least one nonsteroidal anti-
inflammatory drug, with ketoprofen photoallergy being most frequent 
(5 patients, in each case clinically relevant), followed by etofenamate 
(4 non-relevant reactions) and diclofenac (1 relevant reaction). Five pa-
tients were positive to at least one organic sunscreen, most frequently 
to benzophenone-3 (2 patients). “Classical” contact allergy to tested 
photohaptens was found in 15 persons, including 7 with coexisting 
photoallergy. In conclusion, patients requiring diagnostic work-up for 
photoallergy constitute a relevant group among dermatology patients, 
therefore, it seems advisable that all second-level dermatology referral 
centers be capable of photopatch testing. Due attention should also be 
paid to photoallergy in dermatology training.
KeY wORDS: photoallergy, photopatch test, photoallergic contact der-
matitis, dermatology patients, epidemiology
InTRODUCTIOn
Photoallergic contact dermatitis (PhotoACD) is 
a variant of allergic contact dermatitis (ACD), an in-
flammatory skin disease initiated by specific immune 
reactions to an exogenous hapten. It occurs in indi-
viduals with previously acquired contact allergy (type 
IV hypersensitivity reaction) following re-exposure to 
the sensitizing hapten (1). In the photoallergic variant, 
subsequent irradiation, typically with ultraviolet (UV) 
light, is required to initiate the pathologic processes. 
The photons deliver energy for either creating cova-
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lent bonds between hapten and endogenous protein 
(formation of antigenic photoadducts), or converting 
a prohapten into the actual sensitizing hapten (2). 
Further immune and inflammatory processes seem 
not to differ between photoallergic and “classical” (i.e. 
not dependent on irradiation) ACD (3).
In spite of the fact that patients with PhotoACD 
outnumber those with phototoxic drug reactions (4), 
health professionals seem to be much more aware of 
the latter ones. This may be due to insufficient knowl-
edge and underuse of photopatch tests in dermatol-
ogy practice. Facing the growing problem of allergic 
skin diseases, there is a need for improving allergy 
services within dermatology (5). In order to achieve 
this, the accessibility of centers capable of diagnosing 
PhotoACD, as well as the amount of time assigned to 
teaching dermatology residents about photoallergy 
should be adjusted to better reflect the frequency of 
patients requiring diagnostic work-up for photoal-
lergy. Unfortunately, no data are available on the fre-
quency of PhotoACD among dermatology patients 
to provide solid foundation for such adjustments. The 
aim of the present study was, therefore, to analyze 
the frequency of patients requiring diagnostic work-
up for PhotoACD among consecutive dermatology 
outpatients, and to identify the causative photosen-
sitizers.
PATIenTS AnD MeThODS
This prospective observational study commenced 
in February 2010 and was continued until the total 
number of consecutive patients referred for the first 
time to our dermatology outpatient clinic reached 
1000, which happened in February 2012. From this 
cohort, all patients with suspected photodermatosis 
were routinely qualified for photopatch testing. The 
inclusion criterion was a history of chronic or recur-
rent dermatitis of uncovered skin areas, or dermati-
tis induced or aggravated by exposure to light (6). 
All patients were photopatch tested to the baseline 
series of the European Multi-Centre Photopatch Test 
Study (EMCPPTS) taskforce (7), as listed in Table 1. 
Nineteen patients were additionally tested to four 
organic sunscreens: 4-aminobenzoic acid (PABA) 10% 
in petrolatum (pet.), 2-ethylhexyl-4-dimethylami-
nobenzoate (EHDAB, syn. octyldimethyl PABA) 10% 
pet., 2-hydroxy-4-methoxy-4’-methyl-benzophenone 
(benzophenone 10) 10% pet., and terepthalylidene 
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Table 1. Test series of the European Multi-Centre Photopatch Test Study taskforce (7)
No. Hapten CAS number Test preparation
1 Butyl methoxydibenzoylmethane 70356-09-1 10% pet.
2 Homosalate 8045-71-4 10% pet.
3 4-Methylbenzylidene camphor 36861-47-9 10% pet.
4 Benzophenone-3 (Oxybenzone) 131-57-7 10% pet.
5 Ethylhexyl methoxycinnamate 5466-77-3 10% pet.
6 Phenylbenzimidazole sulfonic acid 27503-81-7 10 % pet.
7 Benzophenone 4 (Sulisobenzone) 4065-45-6 2% pet.
8 Drometrizole trisiloxane 155633-54-8 10% pet.
9 Octocrylene 6197-30-4 10% pet.
10 Ethylhexyl salicylate 118-60-5 10% pet.
11 Ethylhexyl triazone (Octyl triazone) 88122-99-0 10% pet.
12 Isoamyl-p-methoxycinnamate 71617-10-2 10% pet.
13 Terepthalylidene dicamphor sulphonic acid 90457-82-2 10% aqua
14 bis-Ethylhexyloxyphenol methoxyphenyl triazine 187393-00-6 10% pet.
15 Methylene bis-benzotriazolyl tetramethylbutylphenol (Bisoctrizole) 103597-45-1 10% pet.
16 Diethylamino hydroxybenzoyl hexyl benzoate 302776-68-7 10% pet.
17 Disodium phenyl dibenzimidazole tetrasulfonate 180898-37-7 10% pet.
18 Diethylhexyl butamido triazone 154702-15-5 10% pet.
19 Polysilicone-15 207574-74-1 10% pet.
20 Ketoprofen 22071-15-4 1% pet.
21 Etofenamate 30544-47-9 2% pet.
22 Piroxicam 36322-90-4 1% pet.
23 Diclofenac 15307-79-6 5% pet.
24 Ibuprofen 15687-27-1 5% pet.
25 Petrolatum (pet.) – control - -
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dicamphor sulfonic acid 10% in aqua. Ten patients 
were additionally tested to the Scandinavian Photo-
patch Test Series (Chemotechnique Diagnostics, Swe-
den). Patients’ own drugs or cosmetics were tested 
in individual cases, whenever it seemed relevant. 
Patch tests were mounted in IQ Ultra test units (Che-
motechnique Diagnostics, Sweden) on the patient’s 
back in two identical sets mounted in and kept under 
occlusion for 48 hours. After removal of the mount-
ing material, one set was irradiated with 5 J/cm2 UVA 
using Waldmann 801 AL phototherapy unit, while the 
non-irradiated set served as the reference. Skin reac-
tions were recorded 24 and 48 hours after irradiation. 
The presence of an inflammatory reaction in the ir-
radiated set and no reaction to the same hapten in 
the non-irradiated area was interpreted as confirma-
tion of photoallergy. In case of positive reactions to a 
hapten both on irradiated and non-irradiated site, the 
“classical” contact allergy was recognized (8).
ReSUlTS
Among 1000 consecutive dermatology outpa-
tients, 36 persons (3.6%; 95% confidence interval (CI): 
2.4-4.8%) were qualified for photopatch testing based 
on their symptoms: 21 females and 15 males aged 6 
to 72 (median 31) years. The total number of patients 
requiring patch tests during the study period amount-
ed to 205, thus the percentage of photo-patch tested 
patients among all patients qualified for patch testing 
of any kind was 17.5% (95%CI: 12.2-22.8%). Photo-
ACD was confirmed in 15 (1.5%; 0.7-2.3%) persons, 7 
females and 8 males aged 6 to 60 (median 33) years. 
Twelve (1.2%; 0.5-1.9%) patients developed positive 
photoallergic reactions to at least one hapten of the 
EMCPPTS series, including nine reacting to at least one 
nonsteroidal antiinflammatory drug (NSAID) and five 
to at least one organic sunscreen (Table 2). Five pa-
tients developed photoallergic response to more than 
one photohapten from the EMCPPTS series (Table 3). 
Results of testing 10 patients from this group to the 
Scandinavian Photopatch Test Series are collated in 
Table 4. No reactions were seen to additional organic 
sunscreens tested in 19 of the 36 patients. Topical ke-
toprofen preparations predominated among patients’ 
own products brought for testing: three out of five 
ketoprofen-photoallergic patients brought one each 
Ketoprom® gel, Ketonal® gel, and Fastum® gel (all con-
taining 2.5% ketoprofen) as suspected causes of their 
dermatitis, which was confirmed by photopatch tests. 
In one patient, photoallergic reactions to Advantan® 
cream and Nanobase® cream were observed, with all 
other tests negative. Another patient proved photo-
allergic to Vichy Capital Soleil® sunscreen. Another 
patient indicated TerbiGen® tablets as the suspected 
cause, and indeed proved photoallergic to terbin-
afine, which has been described in detail elsewhere 
(9). “Classical” contact allergy to the tested photohap-
tens was found in 15 out of 36 patients qualified for 
photopatch testing, including seven patients with co-
existing photoallergy and “classical” contact allergy.
Table 2. Rates of positive photopatch test results to haptens from the European Multi-Centre Photopatch Test 
Study series, routine testing (N=36)
Hapten Photoallergy “Classical” 
contact allergy
nSAID
Ketoprofen 1% pet. 5 (13.9%) 0
Etofenamate 2% pet. 4 (11.1%) 1 (2.8%)
Diclofenac 5% pet. 1 (2.8%) 0
Sunscreen
Benzophenone 3 (Oxybenzone)10% pet. 2 (5.6%) 0
Benzophenone 4 (Sulisobenzone) 2% pet. 1 (2.8%) 1 (2.8%)
Methylene bis-benzotriazolyl tetramethylbutylphenol (Bisoctrizole) 10% pet. 1 (2.8%) 1 (2.8%)
Phenylbenzimidazol sulfonic acid 10% pet. 1 (2.8%) 0
Ethylhexyl triazone (EHT, Octyl triazone) 10% pet. 1 (2.8%) 0
Diethylamino hydroxybenzoyl hexyl benzoate 10% pet. 1 (2.8%) 0
Ethylhexyl-methoxycinnamate 10% pet. 0 1 (2.8%)
Octocrylene 10% pet. 0 1 (2.8%)
Polysilicone-15 10% pet. 0 1 (2.8%)
Other substances in this series that remained negative in all patients tested: butyl-methoxy-dibenzoylmethane 10% pet.; 
homosalate 10% pet.; 4-methylbenzylidene camphor 10% pet.; drometrizole trisiloxane 10% aqua; ethylhexyl salicylate 
10% pet.; isoamyl-p-methoxycinnamate 10% pet.; bis-ethylhexyloxyphenol methoxyphenol triazine 10% pet.; disodium 
phenyl dibenzimidazole tetrasulfonate 10% pet.; diethylhexyl butamido triazone 10% pet.; piroxicam 1% pet.; ibuprofen 
5% pet.; pure petrolatum as control.
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DISCUSSIOn
The present study demonstrated ketoprofen to 
be a potent photosensitizer. Until 2011, topical keto-
profen preparations were sold in Poland as over-the-
counter drugs. During this period, TV networks were 
regularly broadcasting commercials featuring young 
people with sport injuries, who could continue their 
outdoor activities after using the advertised keto-
profen preparations, which ironically seems to be a 
blueprint for acquiring photoallergy to this drug. Ke-
toprofen, nevertheless, could never match the popu-
larity of another NSAID, ibuprofen: in a recent survey, 
16% of 130 young people admitted using ibuprofen 
regularly, while none in this group reported ever us-
ing ketoprofen (10). In spite of such clear ibuprofen 
predominance, photosensitization to ketoprofen was 
found in five participants of the present study, whilst 
none reacted to ibuprofen, which was also included 
in the routine photopatch test series. This suggests 
that ketoprofen may possess certain biological prop-
erties predisposing to photosensitization, in analogy 
with the most frequent “classical” hapten nickel that 
has sensitized approximately 65 million people in Eu-
rope due to widespread exposure (11,12), but also its 
unique biological properties, as reviewed elsewhere 
(13). Photosensitizing potency of ketoprofen calls for 
appropriate actions, like placing a black box warn-
ing on the product package that the drug must not 
be applied on sun-exposed skin areas or taken orally 
before sun exposure. With regard to reducing the risk 
of photosensitization to ketoprofen, a change is pro-
posed of drug delivery route to the transdermal deliv-
ery system covered with a UV-opaque material (e.g., 
a layer of metal foil). Data from pharmacodynamics 
and phototosensitivity studies indicate, however, that 
such UV protection should be continued for 2 weeks 
after concluding ketoprofen application, which may 
seem rather unpractical, thus patient compliance is 
not warranted (Dr Richard Guy, symposium commu-
nication in Malmö, Sweden, June 13, 2012). 
In contrast to ketoprofen, where clinical relevance 
of positive photopatch test results was confirmed in 
all patients, etofenamate with a comparable sensiti-
zation rate remains a mystery: all patients with posi-
Table 3. Patients with simultaneous response to more than one photohapten from the European Multi-Cen-
tre Photopatch Test Study series (routine testing, N=36)
Photohapten Patients
M, 31 F, 22 M, 48 M, 34 M, 6
Ketoprofen + +++
Etofenamate +
Benzophenone 3 (Oxybenzone) + +
Benzophenone 4 (Sulisobenzone) +
Diclofenac +
Methylene bis-benzotriazolyl tetramethylbutylphenol (Bisoctrizole) +
Phenylbenzimidazole sulfonic acid +
Diethylamino hydroxybenzoyl hexyl benzoate +
M = male; F = female; photopatch test reactions scored according to the ICDRG scale (8)
Table 4. Positive photopatch test reactions to haptens from the Scandinavian Photopatch Test Series (sup-
plementary testing, N=10)
Hapten Photoallergy ‘Classical’ contact allergy
Fentichlor 1% pet. 1 (10%) 1 (10%)
6-Methylcoumarine 1% pet. 1 (10%) 0
Promethazine hydrochloride 1% pet. 1 (10%) 0
Hexachlorophene 1% pet. 0 4 (40%)
Wood mix 20% pet. 0 2 (20%)
3,4,5-Tribromosalicylanilide 1% pet. 0 1 (10%)
3,4,4-Trichlorocarbanilide (TCC) 1% pet. 0 1 (10%)
Benzophenone 3 is listed in both Scandinavian Photopatch Test Series and European Multi-Centre Photopatch Test 
Study series; results are shown in Table 2. Other substances in Scandinavian series that remained negative in all tested 
patients were: 3,3’,4’,5-tetrachlorosalicylanilide 0.1% pet.; triclosan 2% pet.; (+)-usnic acid 0.1% pet.; atranorin 0.1% pet.; 
balsam of Peru 25% pet.; bithionol 1 % pet.; chlorhexidine digluconate 0.5% aq.; chlorpromazine hydrochloride 0.1% pet.; 
diphenhydramine hydrochloride 1% pet.; evernic acid 0.1% pet.; perfume mix 6% pet.
Spiewak Acta Dermatovenerol Croat
Photoallergic contact dermatitis  2013;21(4):230-235
234 ACTA DERMATOVENEROLOGICA CROATICA
tive photopatch reactions to etofenamate insisted 
that they had never used any of the etofenamate 
preparations available on the market. Cross-reactivity 
with ketoprofen seems not a plausible explanation, 
as co-existence of photoallergies to both these drugs 
was found in only one patient. In the remaining three 
patients, etofenamate positivity was the sole reaction 
observed. With this respect, etofenamate revokes an 
analogy to the “classical” hapten thiomersal (mer-
thiolate), whose high positivity rates combined with 
low clinical relevance have intrigued researchers for 
decades with no definite explanation available until 
now (14). There is some striking difference between 
etofenamate and ketoprofen with regard to their 
biological effects in human keratinocytes; ketopro-
fen demonstrates a clearly phototoxic effect, which 
may contribute to the development of photoallergic 
reactions, while etofenamate exerts an overall toxic 
effect on keratinocytes, which is only aggravated by 
light (15). Further studies are needed to clarify wheth-
er this toxic effect could explain the observed high 
prevalence of clinically non-relevant (i.e. possibly 
toxic) photopatch test reactions.
Five patients demonstrated more than one reac-
tion to photohaptens from the EMCPPTS series, each 
one with an individual pattern (Table 3). Such simul-
taneous positivity may result from either co-sensitiza-
tion (coincidence) or cross-sensitization (structural or 
functional similarity between photohaptens). Simul-
taneous photosensitization to ketoprofen or etof-
enamate in just one out of eight patients photosensi-
tized to either of these drugs seems to hint at a coin-
cidence rather than cross-sensitization. Also, there are 
no reports on the observed cross-reactivity between 
ketoprofen or etofenamate in medical literature to 
date (PubMed and Scopus search on November 1, 
2013). A second patient was simultaneously photo-
sensitized to ketoprofen and benzophenone 3. As ke-
toprofen and benzophenones are structurally related, 
cross-sensitization seems more probable in this case. 
In a previous study in seven ketoprofen-photoallergic 
patients, four patients reacted also to benzophenone 
3 (16). Structural similarities between benzophenone 
3 and benzophenone 4 also hint at cross-sensitiza-
tion in the third patient (Table 3). In case of the two 
remaining patients, there were no previous reports of 
simultaneous photoallergy either to diclofenac and 
methylene bis-benzotriazolyl tetramethylbutylphe-
nol (bisoctrizole) or to phenylbenzimidazole sulfonic 
acid and diethylamino hydroxybenzoyl hexyl ben-
zoate, which put together with the structural differ-
ences of the chemicals hints at co-sensitization rather 
than cross-sensitization.
COnClUSIOn 
Patients requiring diagnostic work-up for photo-
allergy constitute a relevant group among dermatol-
ogy outpatients, therefore, it seems advisable that all 
second-level dermatology referral centers be capable 
of photopatch testing in patients with symptoms sug-
gesting this pathology. Also, due attention should be 
paid to the problem of photoallergy in the dermatol-
ogy teaching curricula, both for medical students and 
for dermatology residents.
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